KPTI (Karyopharm Therapeutics) Cash And Cash Equivalents : $38.8 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Karyopharm Therapeutics Cash And Cash Equivalents?

Karyopharm Therapeutics's quarterly cash and cash equivalents declined from Sep. 2024 ($72.83 Mil) to Dec. 2024 ($62.48 Mil) but then stayed the same from Dec. 2024 ($62.48 Mil) to Mar. 2025 ($38.78 Mil).

Karyopharm Therapeutics's annual cash and cash equivalents declined from Dec. 2022 ($135.19 Mil) to Dec. 2023 ($52.23 Mil) but then increased from Dec. 2023 ($52.23 Mil) to Dec. 2024 ($62.48 Mil).

Karyopharm Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Karyopharm Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Cash And Cash Equivalents Chart

Karyopharm Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

85.92

190.46

135.19

52.23

62.48

Karyopharm Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															30.63	84.77	72.83	62.48	38.78

Karyopharm Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Karyopharm Therapeutics (NAS:KPTI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Karyopharm Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (NAS:KPTI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

25K0:Germany

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Executives

Richard A. Paulson	director, officer: President and CEO	85 WELLS AVENUE, NEWTON MA 02459
Stuart Poulton	officer: EVP, Chief Development Officer	85 WELLS AVENUE, NEWTON MA 02459
Michael Mano	officer: SVP, General Counsel&Secretary	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Sohanya Roshan Cheng	officer: SVP Sales & Commercial Ops	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459
Reshma Rangwala	officer: EVP & Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael Mason	officer: EVP, CFO, Treasurer	300 3RD STREET, CAMBRIDGE MA 02142
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Garen G Bohlin	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Zhen Su	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Stephen Mitchener	officer: SVP, Chief Business Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Ran Frenkel	officer: EVP, WW Development Operations	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Jatin Shah	officer: EVP, Chief Medical Officer	C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459
Sharon Shacham	officer: C.S.O & Pres. of Res & Develop	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Kauffman	director, officer: President, C.E.O., C.M.O.	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Peter Honig	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037